Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akcea Therapeutics, Inc. stock logo
AKCA
Akcea Therapeutics
$18.17
$18.16
$8.00
$21.70
$1.85B1.45361,806 shsN/A
Arvinas, Inc. stock logo
ARVN
Arvinas
$34.00
-2.6%
$42.95
$13.57
$53.08
$2.32B1.94725,512 shs632,903 shs
Innoviva, Inc. stock logo
INVA
Innoviva
$15.17
+1.6%
$15.05
$11.37
$16.86
$959.20M0.57681,284 shs1.49 million shs
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
$17.68
+3.5%
$19.40
$10.65
$22.09
$1.25B0.27402,732 shs611,398 shs
Tricida, Inc. stock logo
TCDA
Tricida
$0.13
$0.09
$13.85
$6.01M0.2217.62 million shs31.13 million shs
A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for May 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akcea Therapeutics, Inc. stock logo
AKCA
Akcea Therapeutics
0.00%0.00%0.00%0.00%0.00%
Arvinas, Inc. stock logo
ARVN
Arvinas
+0.52%+0.52%-16.71%-4.07%+22.28%
Innoviva, Inc. stock logo
INVA
Innoviva
-0.13%+3.68%-1.06%-10.44%+24.62%
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
+1.09%-1.98%-14.40%-8.49%+46.61%
Tricida, Inc. stock logo
TCDA
Tricida
0.00%0.00%0.00%0.00%0.00%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Akcea Therapeutics, Inc. stock logo
AKCA
Akcea Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
Arvinas, Inc. stock logo
ARVN
Arvinas
2.6994 of 5 stars
4.40.00.00.02.82.50.6
Innoviva, Inc. stock logo
INVA
Innoviva
1.4386 of 5 stars
0.02.00.04.22.71.71.3
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
2.9713 of 5 stars
3.52.00.00.02.43.31.3
Tricida, Inc. stock logo
TCDA
Tricida
N/AN/AN/AN/AN/AN/AN/AN/A

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akcea Therapeutics, Inc. stock logo
AKCA
Akcea Therapeutics
N/AN/AN/AN/A
Arvinas, Inc. stock logo
ARVN
Arvinas
2.88
Moderate Buy$59.7375.69% Upside
Innoviva, Inc. stock logo
INVA
Innoviva
N/AN/AN/AN/A
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
3.00
Buy$30.0069.68% Upside
Tricida, Inc. stock logo
TCDA
Tricida
N/AN/AN/AN/A

Current Analyst Ratings

Latest KNSA, AKCA, TCDA, ARVN, and INVA Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
4/23/2024
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$30.00
4/12/2024
Arvinas, Inc. stock logo
ARVN
Arvinas
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$90.00 ➝ $87.00
4/2/2024
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$28.00 ➝ $30.00
3/25/2024
Arvinas, Inc. stock logo
ARVN
Arvinas
Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$65.00
2/29/2024
Arvinas, Inc. stock logo
ARVN
Arvinas
Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOverweight ➝ Overweight$26.00 ➝ $60.00
2/28/2024
Arvinas, Inc. stock logo
ARVN
Arvinas
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$90.00
2/28/2024
Arvinas, Inc. stock logo
ARVN
Arvinas
BMO Capital Markets
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$89.00 ➝ $90.00
2/28/2024
Arvinas, Inc. stock logo
ARVN
Arvinas
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Outperform$95.00 ➝ $80.00
2/28/2024
Arvinas, Inc. stock logo
ARVN
Arvinas
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetOutperform ➝ Outperform$33.00 ➝ $59.00
2/28/2024
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
Wedbush
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform$28.00
2/22/2024
Arvinas, Inc. stock logo
ARVN
Arvinas
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
(Data available from 4/23/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akcea Therapeutics, Inc. stock logo
AKCA
Akcea Therapeutics
$488.54M3.78$0.51 per share35.54$5.78 per share3.14
Arvinas, Inc. stock logo
ARVN
Arvinas
$78.50M29.59N/AN/A$11.99 per share2.84
Innoviva, Inc. stock logo
INVA
Innoviva
$310.46M3.09$3.55 per share4.27$10.66 per share1.42
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
$270.26M4.62N/AN/A$6.23 per share2.84
Tricida, Inc. stock logo
TCDA
Tricida
N/AN/AN/AN/AN/AN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akcea Therapeutics, Inc. stock logo
AKCA
Akcea Therapeutics
$40.77M$0.48N/AN/AN/A-12.34%-8.94%-8.02%N/A
Arvinas, Inc. stock logo
ARVN
Arvinas
-$367.30M-$6.50N/AN/AN/A-185.09%-70.24%-31.79%5/3/2024 (Estimated)
Innoviva, Inc. stock logo
INVA
Innoviva
$179.72M$2.186.96N/A57.89%30.37%15.70%5/14/2024 (Estimated)
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
$14.08M$0.1898.23N/AN/A5.11%-6.12%-5.20%4/23/2024 (Confirmed)
Tricida, Inc. stock logo
TCDA
Tricida
-$176.57M-$2.36N/AN/AN/AN/AN/A-103.81%N/A

Latest KNSA, AKCA, TCDA, ARVN, and INVA Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
4/23/2024N/A
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
-$0.14-$0.25-$0.11N/A$76.97 million$79.90 million  
2/29/2024Q4 2023
Innoviva, Inc. stock logo
INVA
Innoviva
N/A$0.76+$0.76$0.76N/A$85.84 million
2/28/2024Q4 2023
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
-$0.11$0.04+$0.15-$0.27$72.31 million$83.40 million
2/27/2024Q4 2023
Arvinas, Inc. stock logo
ARVN
Arvinas
-$1.15-$2.53-$1.38-$2.53$38.91 million($43.10) million  

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Akcea Therapeutics, Inc. stock logo
AKCA
Akcea Therapeutics
N/AN/AN/AN/AN/A
Arvinas, Inc. stock logo
ARVN
Arvinas
N/AN/AN/AN/AN/A
Innoviva, Inc. stock logo
INVA
Innoviva
N/AN/AN/AN/AN/A
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
N/AN/AN/AN/AN/A
Tricida, Inc. stock logo
TCDA
Tricida
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akcea Therapeutics, Inc. stock logo
AKCA
Akcea Therapeutics
N/A
12.17
11.78
Arvinas, Inc. stock logo
ARVN
Arvinas
N/A
4.98
4.98
Innoviva, Inc. stock logo
INVA
Innoviva
0.66
9.03
7.96
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
N/A
4.34
3.85
Tricida, Inc. stock logo
TCDA
Tricida
N/A
4.87
4.87

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Akcea Therapeutics, Inc. stock logo
AKCA
Akcea Therapeutics
19.27%
Arvinas, Inc. stock logo
ARVN
Arvinas
95.19%
Innoviva, Inc. stock logo
INVA
Innoviva
99.12%
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
53.95%
Tricida, Inc. stock logo
TCDA
Tricida
N/A

Insider Ownership

CompanyInsider Ownership
Akcea Therapeutics, Inc. stock logo
AKCA
Akcea Therapeutics
1.50%
Arvinas, Inc. stock logo
ARVN
Arvinas
5.23%
Innoviva, Inc. stock logo
INVA
Innoviva
1.40%
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
54.23%
Tricida, Inc. stock logo
TCDA
Tricida
35.60%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Akcea Therapeutics, Inc. stock logo
AKCA
Akcea Therapeutics
248101.60 millionN/AOptionable
Arvinas, Inc. stock logo
ARVN
Arvinas
44568.31 million64.74 millionOptionable
Innoviva, Inc. stock logo
INVA
Innoviva
11263.23 million62.34 millionOptionable
Kiniksa Pharmaceuticals, Ltd. stock logo
KNSA
Kiniksa Pharmaceuticals
29770.61 million32.32 millionOptionable
Tricida, Inc. stock logo
TCDA
Tricida
5755.67 million35.85 millionNot Optionable

KNSA, AKCA, TCDA, ARVN, and INVA Headlines

SourceHeadline
SierraConstellation Partners Receives Industry Recognition for Work with TricidaSierraConstellation Partners Receives Industry Recognition for Work with Tricida
finance.yahoo.com - February 6 at 10:02 AM
Tricida Inc (TCDAQ)Tricida Inc (TCDAQ)
es.investing.com - January 13 at 10:29 AM
Emerging Therapies in the Treatment of Clostridium difficile-Associated DiseaseEmerging Therapies in the Treatment of Clostridium difficile-Associated Disease
medscape.com - May 30 at 8:27 AM
Vaniam Group Hires Paula Franson to Lead Clinical Strategy & Solutions - Yahoo FinanceVaniam Group Hires Paula Franson to Lead Clinical Strategy & Solutions - Yahoo Finance
news.google.com - April 18 at 12:45 AM
Metabolic Acidosis Market to Witness Growth by 2032, Estimates ... - Digital JournalMetabolic Acidosis Market to Witness Growth by 2032, Estimates ... - Digital Journal
news.google.com - April 17 at 7:44 PM
Real-time PCR as a Diagnostic Tool for Bacterial DiseasesReal-time PCR as a Diagnostic Tool for Bacterial Diseases
medscape.com - April 12 at 11:47 PM
Chronic Kidney Disease Drugs Market Expected To Propel Market ... - Digital JournalChronic Kidney Disease Drugs Market Expected To Propel Market ... - Digital Journal
news.google.com - April 10 at 8:38 AM
Chronic Kidney Disease Drugs Market Huge Growth in Future ... - Digital JournalChronic Kidney Disease Drugs Market Huge Growth in Future ... - Digital Journal
news.google.com - April 6 at 7:54 AM
Tricida Heading For Ch. 11 Confirmation Fight With Creditors - Law360Tricida Heading For Ch. 11 Confirmation Fight With Creditors - Law360
news.google.com - March 24 at 11:19 PM
Alicia Dixon Joins COPILOT Provider Support Services as VP of Strategy Development & Execution - Yahoo FinanceAlicia Dixon Joins COPILOT Provider Support Services as VP of Strategy Development & Execution - Yahoo Finance
news.google.com - March 14 at 3:50 PM
Alicia Dixon Joins COPILOT Provider Support Services as VP of ... - Yahoo FinanceAlicia Dixon Joins COPILOT Provider Support Services as VP of ... - Yahoo Finance
news.google.com - March 14 at 10:49 AM
Tricida Heads To Ch. 11 Mediation Over Creditor Plan Issues - Law360Tricida Heads To Ch. 11 Mediation Over Creditor Plan Issues - Law360
news.google.com - March 6 at 10:59 PM
Troubled Adamis To Merge With Private DMK, Focus On ... - ScripTroubled Adamis To Merge With Private DMK, Focus On ... - Scrip
news.google.com - March 1 at 12:17 PM
Release Opt Out Trips Up Tricida Ch. 11 Disclosure Approval - Law360Release Opt Out Trips Up Tricida Ch. 11 Disclosure Approval - Law360
news.google.com - February 27 at 8:43 PM
Renibus Buys Tricidas Kidney Drug Veverimer In Ch. 11 Sale - Law360Renibus Buys Tricida's Kidney Drug Veverimer In Ch. 11 Sale - Law360
news.google.com - February 21 at 8:22 PM
STONEHILL CAPITAL MANAGEMENT LLC Buys 2, Sells 3 in 4th ... - GuruFocus.comSTONEHILL CAPITAL MANAGEMENT LLC Buys 2, Sells 3 in 4th ... - GuruFocus.com
news.google.com - February 18 at 1:53 AM
Top 5 4th Quarter Trades of ORBIMED ADVISORS LLC - GuruFocus.comTop 5 4th Quarter Trades of ORBIMED ADVISORS LLC - GuruFocus.com
news.google.com - February 18 at 1:53 AM
Tricida, Inc. (TCDA) Stock Historical Prices & Data - Yahoo FinanceTricida, Inc. (TCDA) Stock Historical Prices & Data - Yahoo Finance
finance.yahoo.com - February 14 at 7:22 PM
Rising Serum Bicarbonate Lowers CKD Progression Risk in ... - Renal and Urology NewsRising Serum Bicarbonate Lowers CKD Progression Risk in ... - Renal and Urology News
news.google.com - February 8 at 7:43 AM
Firm Retention Summary: Tricida Inc.Firm Retention Summary: Tricida Inc.
wsj.com - February 3 at 3:38 PM
Tricidas Chapter 11 Liquidation – Global Legal Chronicle - Global Legal ChronicleTricida's Chapter 11 Liquidation – Global Legal Chronicle - Global Legal Chronicle
news.google.com - January 29 at 8:47 AM
Tricida Gets OK To Seek Stalking Horse For Ch. 11 Auction - Law360Tricida Gets OK To Seek Stalking Horse For Ch. 11 Auction - Law360
news.google.com - January 26 at 6:43 PM
Weak Fundamental Momentum Drags Tricida Inc. (TCDA) Lower - Marketing SentinelWeak Fundamental Momentum Drags Tricida Inc. (TCDA) Lower - Marketing Sentinel
news.google.com - January 24 at 2:09 PM
Tricida Inc. (TCDA): This Stock is set to Soar Above its Peers - Invest ChronicleTricida Inc. (TCDA): This Stock is set to Soar Above its Peers - Invest Chronicle
news.google.com - January 24 at 9:08 AM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

Akcea Therapeutics logo

Akcea Therapeutics

NASDAQ:AKCA
Akcea Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs to treat patients with serious and rare diseases in the United States and internationally. The company offers TEGSEDI, which is designed to reduce the production of transthyretin protein. It develops WAYLIVRA, which has completed Phase III clinical study for the treatment of familial chylomicronemia syndrome; and that is in Phase III clinical study for the treatment of familial partial lipodystrophy. The company also develops AKCEA-APO(a)-LRx, which has completed Phase IIb clinical study for treating patients suffering with hyperlipoproteinemia; AKCEA-ANGPTL3-LRx that has completed Phase IIb clinical study for the treatment of multiple lipid disorders; and AKCEA-APOCIII-LRx, which is in Phase II study for the treatment of cardiovascular disease due to elevated triglyceride levels, as well as AKCEA-TTR-LRx to treat the broad population of patients with hereditary and wild-type forms of transthyretin amyloidosis. It has strategic collaboration with Novartis Pharma AG and PTC Therapeutics International Limited. The company was incorporated in 2014 and is headquartered in Boston, Massachusetts. Akcea Therapeutics, Inc. operates as a subsidiary of Ionis Pharmaceuticals, Inc.
Arvinas logo

Arvinas

NASDAQ:ARVN
Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.
Innoviva logo

Innoviva

NASDAQ:INVA
Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
Kiniksa Pharmaceuticals logo

Kiniksa Pharmaceuticals

NASDAQ:KNSA
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.
Tricida logo

Tricida

NASDAQ:TCDA
Tricida, Inc. is a pharmaceutical company. It focuses on the development and commercialization of its product, TRC101, a non-absorbed, orally-administered polymer drug designed to treat metabolic acidosis in patients with chronic kidney disease. The company was founded by Gerrit Klaerner and Craig Jon Hawker on May 22, 2013 and is headquartered in South San Francisco, CA.